Trifluridine/tipiracil plus bevacizumab (FTD/TPI plus BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer (mCRC): Results of a meta-analysis.

被引：0
|
作者：
Yoshino, Takayuki
Taieb, Julien
Andre, Thierry
Kuboki, Yasutoshi
Pfeiffer, Per
Kumar, Amit
Hochster, Howard S.
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan
[2] Paris Descartes Univ, Hop Europ een Georges Pompidou, Paris, France
[3] Hop St Antoine, Paris, France
[4] Natl Canc Ctr Hosp East, Kashiwa, Japan
[5] Odense Univ Hosp, Odense, Denmark
[6] SmartAnalyst India Pvt Ltd, Gurugram, Haryan, India
[7] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3568
引用
收藏
页数：1
相关论文
共 50 条
  • [21] TALLISUR Phase IV study of trifluridine/tipiracil (FTD/TPI) in patients with pre-treated metastatic Colorectal Cancer (mCRC) - subgroup analysis
    Karthaus, M.
    Weiss, L.
    Riera-Knorrenschild, J.
    Kretschmar, A.
    Welslau, M.
    Vehling-Kaiser, U.
    Pelz, H.
    Ettrich, T.
    Held, S.
    Klein, A.
    Hess, J.
    Reislaender, T.
    Heinemann, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 160 - 160
  • [22] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study
    Li, Rongrong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Liu, Zhen-yang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis
    de Moraes, Francisco Cezar Aquino
    Pessoa, Felipe Dirceu Dantas Leite
    Ribeiro, Caio Henrique Duarte de Castro
    Fernandes, Marianne Rodrigues
    Burbano, Rommel Mario Rodriguez
    dos Santos, Ney Pereira Carneiro
    BMC CANCER, 2024, 24 (01)
  • [24] Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
    Chida, Keigo
    Kotani, Daisuke
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Shitara, Kohei
    Kojima, Takashi
    Taniguchi, Hiroya
    Watanabe, Jun
    Endo, Itaru
    Yoshino, Takayuki
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [25] Preclinical analysis and clinical validation to identify biomarkers for trifluridine/tipiracil (FTD/TPI) efficacy with or without bevacizumab in patients with metastatic colorectal cancer.
    Suenaga, Mitsukuni
    Mashima, Tetsuo
    Kawata, Naomi
    Dan, Shingo
    Seimiya, Hiroyuki
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 230 - 230
  • [26] Effect of trifluridine/tipiracil (FTD/TPI) in combination with bevacizumab (bev) in patients treated in SUNLIGHT by clinical prognostic factors at baseline
    Tabernero, J.
    Taieb, J.
    Fakih, M.
    Ciardiello, F.
    Van Cutsem, E.
    Roby, L.
    Yao, W.
    Choucair, E.
    Prager, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S444 - S444
  • [27] Identification of the optimal patients for trifluridine/tipiracil (FTD/TPI) treatment in mCRC: A Spanish real-world analysis
    Fernandez Montes, Ana Fernandez
    Vazquez Rivera, Francisca
    Martinez Lago, Nieves
    Covela Rua, Marta
    Cousillas Castineiras, Antia
    Gonzalez Villarroel, Paula
    De la Camara, Juan
    Mendez Mendez, Carlos
    Salgado Fernandez, Mercedes
    Candamio Folgar, Sonia
    Reboredo Lopez, Margarita
    Carmona Campos, Marta
    Gallardo Martin, Elena
    Jorge Fernandez, Monica
    Pellon Augusto, Maria Luz
    Garcia Gomez, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [28] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Horasawa, Satoshi
    Kaneko, Asumi
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Bando, Hideaki
    Taniguchi, Hiroya
    Shitara, Kohei
    Kojima, Takashi
    Tsuji, Akihito
    Yoshino, Takayuki
    BMC CANCER, 2019, 19 (01)
  • [29] Comparison of the real-world adherence and compliance patterns with trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).
    Patel, Anuj K.
    Duh, Mei Sheng
    Barghout, Victoria
    Yenikomshian, Mihran Ara
    Xiao, Yongling
    Wynant, Willy
    Tabesh, Majid
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [30] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Daisuke Kotani
    Yasutoshi Kuboki
    Satoshi Horasawa
    Asumi Kaneko
    Yoshiaki Nakamura
    Akihito Kawazoe
    Hideaki Bando
    Hiroya Taniguchi
    Kohei Shitara
    Takashi Kojima
    Akihito Tsuji
    Takayuki Yoshino
    BMC Cancer, 19
12345